Table 1. Patient characteristics . . .... | American Society of Hematology

Table 1.

Patient characteristics

			Before ART					Baseline of STI trial					After STI
			Months HIV-1 positive		RNA copies per milliliter^*		Months of VL less than 50 copies per milliliter	CD4 cells per cubic millimeter	RNA copies per milliliter†	CD4 cells per cubic millimeter	Coreceptor usage
Code	Age, y	Sex	Months HIV-1 positive		RNA copies per milliliter^*	Clinical stage	Months of VL less than 50 copies per milliliter	CD4 cells per cubic millimeter	RNA copies per milliliter†	CD4 cells per cubic millimeter		ART				First cycle	Fifth cycle	HIV subtype	Δlog VL‡	Virus control§
Group A: Zurich
102	40	M	>24	C	561 831	AZT, 3TC, IDV	32	723	76 805	491	R5	R5	B	0.86	No
106	40	M	>24	A	402	AZT, 3TC, NFV	36	878	5 128	650	ND	R5	B	−1.11	High
107	45	F	>24	A	5 216	AZT, 3TC	25	544	2 551	537	ND	R5	B	0.31	High
109	37	M	>24	B	34 752	AZT, 3TC, RTV	31	1 115	148 191	806	R5	R5	B	−0.63	No
111	37	M	>24	A	122 729	ddI, d4T, NFV	11	422	22 030	362	R5	R5	B	0.75	No
112	45	M	6-12	A	32 140	AZT, 3TC, IDV	25	347	6 866	431	ND	R5	B	0.67	High
113	59	M	12-24	A	107 303	AZT, 3TC, RTV	20	995	34 110	792	ND	R5	B	0.50	No
114	33	M	>24	A	9 275	AZT, 3TC, RTV	29	907	28 478	784	ND	R5	B	−0.49	No
115	25	M	12-24	A	37 751	d4T, 3TC, NFV	21	570	9 368	558	ND	R5	B	0.61	No
116	52	M	>24	C	467 593	AZT, 3TC, IDV	32	350	31 500	202	R5X4	R5X4	B	1.17	No
117	34	F	12-24	A	29 344	AZT, 3TC, RTV	36	489	13 007	341	ND	R5	B	0.35	High
118	32	M	12-24	A	16 927	AZT, 3TC, IDV	30	832	3 099	785	R5	R5	B	0.74	High
119	36	M	12-24	A	113 052	d4T, 3TC, SQV, RTV	12	440	99 274	394	ND	R5	B	0.06	No
120	54	M	12-24	A	150 390	AZT, 3TC, IDV	28	766	38 252	511	R5	R5	B	0.59	No
121	37	M	3-6	A	164 772	d4T, 3TC, NFV	12	591	67 321	380	R5	R5	B	0.39	No
122	41	M	>24	A	13 317	AZT, 3TC, IDV	30	669	24 982	481	ND	R5	B	−0.27	No
123	40	F	>24	A	14 410	AZT, 3TC, RTV	25	1 335	118	529	ND	R5	B	2.09	High
125	34	F	>24	A	11 298	ddI, d4T, NFV	23	777	4 873	882	R5	R5	E/CRF1	0.37	High
126	50	M	>24	A	63 698	AZT, 3TC, RTV	34	842	19 782	441	ND	R5	B	0.51	No
127	51	F	>24	A	25 417	d4T, 3TC, NFV	22	839	106 923	614	R5	R5	B	−0.62	No
128	42	F	>24	A	9 404	AZT, ddI, NFV	25	749	20 236	949	R5	R5	B	−0.33	No
130	67	M	6-12	A	537	AZT, 3TC, NFV	30	829	107	729	ND	R5	A	0.70	High
Group B: other centers
43	51	M	>24	A	34 493	d4T, ddI	41	666	8 490	466	ND	ND	ND	0.61	No
79	44	M	>24	A	10 599	AZT, 3TC, IDV	33	697	5 847	465	ND	ND	ND	0.26	High
105	36	F	>24	A	47 837	d4T, ddI, NFV	24	703	5 013	668	ND	ND	ND	0.98	High
140	56	M	>24	A	20 964	AZT, 3TC, RTV, SQV	19	480	2 375	372	ND	ND	ND	0.95	High
164	33	F	>24	A	13 322	AZT, 3TC, NFV	19	717	6 094	493	ND	ND	ND	0.34	No
208	45	M	>24	A	13 322	AZT, 3TC, NFV	11	571	11 472	386	ND	ND	ND	0.06	High
260	32	F	>24	A	16 000	d4T, 3TC, IDV	17	1 070	12 188	1 330	ND	ND	ND	0.12	No
275	35	M	>24	A	33 709	d4T, 3TC, NFV	22	599	13 340	466	ND	ND	ND	0.40	No
288	40	M	>24	A	14 027	d4T, 3TC, NFV	16	490	22 651	515	ND	ND	ND	−0.21	No
351	39	M	>24	A	510	AZT, 3TC, RTV	33	1 580	8 601	1 160	ND	ND	ND	−1.23	No
388	48	M	>24	A	36 976	d4T, 3TC, NFV	17	582	28 424	583	ND	ND	ND	0.11	No
401	68	F	12-24	A	54 210	d4T, 3TC, NFV	10	1 322	35 651	759	ND	ND	ND	0.18	No
410	33	F	>24	A	513	AZT, 3TC, RTV	38	852	1 753	542	ND	ND	ND	−0.53	High
455	36	M	>24	A	52 849	d4T, 3TC, NFV	22	616	70 850	554	ND	ND	ND	−0.13	No
580	55	M	>24	A	21 965	d4T, ddI	32	1 143	14 458	971	ND	ND	ND	0.18	No
607	36	M	12-24	A	39 021	d4T, 3TC, NFV	21	565	19 713	437	ND	ND	ND	0.30	No
628	44	F	>24	A	12 394	d4T, 3TC, NFV	26	605	6 862	489	ND	ND	ND	0.26	High
716	34	M	6-12	A	14 031	AZT, 3TC, NFV	9	722	12 888	462	ND	ND	ND	0.04	No
723	22	F	3-6	A	12 005	d4T, 3TC, IDV	16	1 056	3 105	964	ND	ND	ND	0.59	High
826	55	M	>24	A	21 220	ABC, AZT, 3TC	31	952	10 487	717	ND	ND	ND	0.31	High
837	47	M	>24	A	23 146	AZT, 3TC, NFV	32	1 025	7 828	878	ND	ND	ND	0.47	No
904	31	M	>24	A	32 555	AZT, 3TC, NFV	19	804	4 345	1 158	ND	ND	ND	0.87	High
933	42	M	6-12	B	46 073	d4T, RTV, SQV	31	711	15 481	618	ND	ND	ND	0.47	No
957	37	F	12-24	A	4 919	d4T, 3TC, NFV	25	532	17	536	ND	ND	ND	2.46	High

			Before ART					Baseline of STI trial					After STI
			Months HIV-1 positive		RNA copies per milliliter^*		Months of VL less than 50 copies per milliliter	CD4 cells per cubic millimeter	RNA copies per milliliter†	CD4 cells per cubic millimeter	Coreceptor usage
Code	Age, y	Sex	Months HIV-1 positive		RNA copies per milliliter^*	Clinical stage	Months of VL less than 50 copies per milliliter	CD4 cells per cubic millimeter	RNA copies per milliliter†	CD4 cells per cubic millimeter		ART				First cycle	Fifth cycle	HIV subtype	Δlog VL‡	Virus control§
Group A: Zurich
102	40	M	>24	C	561 831	AZT, 3TC, IDV	32	723	76 805	491	R5	R5	B	0.86	No
106	40	M	>24	A	402	AZT, 3TC, NFV	36	878	5 128	650	ND	R5	B	−1.11	High
107	45	F	>24	A	5 216	AZT, 3TC	25	544	2 551	537	ND	R5	B	0.31	High
109	37	M	>24	B	34 752	AZT, 3TC, RTV	31	1 115	148 191	806	R5	R5	B	−0.63	No
111	37	M	>24	A	122 729	ddI, d4T, NFV	11	422	22 030	362	R5	R5	B	0.75	No
112	45	M	6-12	A	32 140	AZT, 3TC, IDV	25	347	6 866	431	ND	R5	B	0.67	High
113	59	M	12-24	A	107 303	AZT, 3TC, RTV	20	995	34 110	792	ND	R5	B	0.50	No
114	33	M	>24	A	9 275	AZT, 3TC, RTV	29	907	28 478	784	ND	R5	B	−0.49	No
115	25	M	12-24	A	37 751	d4T, 3TC, NFV	21	570	9 368	558	ND	R5	B	0.61	No
116	52	M	>24	C	467 593	AZT, 3TC, IDV	32	350	31 500	202	R5X4	R5X4	B	1.17	No
117	34	F	12-24	A	29 344	AZT, 3TC, RTV	36	489	13 007	341	ND	R5	B	0.35	High
118	32	M	12-24	A	16 927	AZT, 3TC, IDV	30	832	3 099	785	R5	R5	B	0.74	High
119	36	M	12-24	A	113 052	d4T, 3TC, SQV, RTV	12	440	99 274	394	ND	R5	B	0.06	No
120	54	M	12-24	A	150 390	AZT, 3TC, IDV	28	766	38 252	511	R5	R5	B	0.59	No
121	37	M	3-6	A	164 772	d4T, 3TC, NFV	12	591	67 321	380	R5	R5	B	0.39	No
122	41	M	>24	A	13 317	AZT, 3TC, IDV	30	669	24 982	481	ND	R5	B	−0.27	No
123	40	F	>24	A	14 410	AZT, 3TC, RTV	25	1 335	118	529	ND	R5	B	2.09	High
125	34	F	>24	A	11 298	ddI, d4T, NFV	23	777	4 873	882	R5	R5	E/CRF1	0.37	High
126	50	M	>24	A	63 698	AZT, 3TC, RTV	34	842	19 782	441	ND	R5	B	0.51	No
127	51	F	>24	A	25 417	d4T, 3TC, NFV	22	839	106 923	614	R5	R5	B	−0.62	No
128	42	F	>24	A	9 404	AZT, ddI, NFV	25	749	20 236	949	R5	R5	B	−0.33	No
130	67	M	6-12	A	537	AZT, 3TC, NFV	30	829	107	729	ND	R5	A	0.70	High
Group B: other centers
43	51	M	>24	A	34 493	d4T, ddI	41	666	8 490	466	ND	ND	ND	0.61	No
79	44	M	>24	A	10 599	AZT, 3TC, IDV	33	697	5 847	465	ND	ND	ND	0.26	High
105	36	F	>24	A	47 837	d4T, ddI, NFV	24	703	5 013	668	ND	ND	ND	0.98	High
140	56	M	>24	A	20 964	AZT, 3TC, RTV, SQV	19	480	2 375	372	ND	ND	ND	0.95	High
164	33	F	>24	A	13 322	AZT, 3TC, NFV	19	717	6 094	493	ND	ND	ND	0.34	No
208	45	M	>24	A	13 322	AZT, 3TC, NFV	11	571	11 472	386	ND	ND	ND	0.06	High
260	32	F	>24	A	16 000	d4T, 3TC, IDV	17	1 070	12 188	1 330	ND	ND	ND	0.12	No
275	35	M	>24	A	33 709	d4T, 3TC, NFV	22	599	13 340	466	ND	ND	ND	0.40	No
288	40	M	>24	A	14 027	d4T, 3TC, NFV	16	490	22 651	515	ND	ND	ND	−0.21	No
351	39	M	>24	A	510	AZT, 3TC, RTV	33	1 580	8 601	1 160	ND	ND	ND	−1.23	No
388	48	M	>24	A	36 976	d4T, 3TC, NFV	17	582	28 424	583	ND	ND	ND	0.11	No
401	68	F	12-24	A	54 210	d4T, 3TC, NFV	10	1 322	35 651	759	ND	ND	ND	0.18	No
410	33	F	>24	A	513	AZT, 3TC, RTV	38	852	1 753	542	ND	ND	ND	−0.53	High
455	36	M	>24	A	52 849	d4T, 3TC, NFV	22	616	70 850	554	ND	ND	ND	−0.13	No
580	55	M	>24	A	21 965	d4T, ddI	32	1 143	14 458	971	ND	ND	ND	0.18	No
607	36	M	12-24	A	39 021	d4T, 3TC, NFV	21	565	19 713	437	ND	ND	ND	0.30	No
628	44	F	>24	A	12 394	d4T, 3TC, NFV	26	605	6 862	489	ND	ND	ND	0.26	High
716	34	M	6-12	A	14 031	AZT, 3TC, NFV	9	722	12 888	462	ND	ND	ND	0.04	No
723	22	F	3-6	A	12 005	d4T, 3TC, IDV	16	1 056	3 105	964	ND	ND	ND	0.59	High
826	55	M	>24	A	21 220	ABC, AZT, 3TC	31	952	10 487	717	ND	ND	ND	0.31	High
837	47	M	>24	A	23 146	AZT, 3TC, NFV	32	1 025	7 828	878	ND	ND	ND	0.47	No
904	31	M	>24	A	32 555	AZT, 3TC, NFV	19	804	4 345	1 158	ND	ND	ND	0.87	High
933	42	M	6-12	B	46 073	d4T, RTV, SQV	31	711	15 481	618	ND	ND	ND	0.47	No
957	37	F	12-24	A	4 919	d4T, 3TC, NFV	25	532	17	536	ND	ND	ND	2.46	High

AZT indicates zidovudine; 3TC, lamivudine; IDV, indinavir; NFV, nelfinavir; ND, not done; RTV, ritonavir; ddI, didanosine; d4T, stavudine; and SQV, saquinavir.

Geometric mean if more than 1 value before initiation of antiretroviral therapy was available.

†

Post-STI viral load plateau: geometric mean of HIV RNA values between weeks 46 and 64. Four patients (patients 102, 109, 116, and 455) had plateau VLs calculated from the 2 or 3 time points just prior to restarting therapy. In 2 patients (patients 107 and 130), the week-46 data point was part of a peak and was therefore omitted from the estimation of the plateau. For the 42 patients who remained off therapy for extended periods, an average of 7.33 data points were used to calculate the plateau VL (range, 3-12 data points).

‡

Improvement of viral set point: log difference between pre-ART VL and post-STI VL.

Control of viremia was defined as VL less than 5000 RNA copies per milliliter for at least 8 weeks between weeks 40 and 76.

View Large

This Feature Is Available To Subscribers Only